Last reviewed · How we verify
NCT05999058
Clinical Study of Lacrimal Drainage Obstruction Diseases Using Dacryoendoscopy
NA trial testing Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation in Lacrimal Duct Obstruction in 522 participants. Completed in 1 November 2023.
1 November 2023
Quick facts
| Lead sponsor | Tianjin Eye Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 522 |
| Start date | 1 November 2019 |
| Primary completion | 1 November 2023 |
| Estimated completion | 1 November 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation
Conditions studied
- Lacrimal Duct Obstruction — all drugs for Lacrimal Duct Obstruction →
Sponsor
Tianjin Eye Hospital
Who can join
Adults 18 to 80, any sex, with Lacrimal Duct Obstruction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Nasolacrimal duct obstruction (NLDO) can manifest as epiphora or recurrent infections with mucopurulent discharge and may even cause social embarrassment. Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation (DLDI) offers direct therapy to the obstructed site, leading to minimal collateral damage external to the target zone. Although the silicone intubation using dacryoendoscopy has increased the success rates, the success rates vary from a low of 51% to a high of 90%. The difference in success rates seems to depend on the site of obstruction, differences in the surgical technique, stringency of definitions of success, and duration of follow-up. The aim of our study was to report the results of DLDI for the management of NLDO, and to identify factors associated with DLDI failure.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical outcomes and prognostic factors in patients with nasolacrimal duct obstruction or stenosis using dacryoendoscopy.
Li H, Li J, Zhang L, Yang L, et al · · 2024 · cited 5× · PMID 39486803 · DOI 10.1136/bmjophth-2024-001743
Verify or expand the search:
- PubMed search for NCT05999058
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Tianjin Eye Hospital trials
Trials by the same sponsor.
- NCT07518316 — Factors Influencing Subjective Visual Quality in Human Eyes · NA · not yet recruiting
- NCT06993077 — Impact of Ultraviolet Radiation and Environmental Factors on Human Ocular Biomechanics · active not recruiting
- NCT06694051 — Application of Phototherapeutic Keratectomy Mode to Mark the Axis of Astigmatism · NA · recruiting
- NCT07244276 — Comparison of Compressed Continuous Suture and Conventional Suture in Pterygium Surgery · NA · recruiting
- NCT07171710 — Efficacy of 0.05% Cyclosporine A Eye Drops Combined With Absorbable Tear Duct Plugs in the Treatment of Dry Eye in Sjögr · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05999058 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Eye Hospital
- Last refreshed: 28 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05999058.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing